^
    7d
    NRG-GY031: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    7d
    NCI-2022-04099: Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    Verzenio (abemaciclib) • ZEN-3694
    8d
    Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    capecitabine • ZEN-3694
    1m
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (clinicaltrials.gov)
    P1, N=30, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694
    1m
    ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Zenith Epigenetics | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    enzalutamide • abiraterone acetate • ZEN-3694
    1m
    Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol (clinicaltrials.gov)
    P1/2, N=40, Enrolling by invitation, Zenith Epigenetics | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    enzalutamide • ZEN-3694
    3ms
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (clinicaltrials.gov)
    P2, N=88, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    KRAS mutation • BRCA2 mutation • BRCA1 mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    3ms
    A Study of ZEN003694 in People With Squamous Cell Lung Cancer (clinicaltrials.gov)
    P2, N=13, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    NSD3 (Nuclear Receptor Binding SET Domain Protein 3)
    |
    ZEN-3694
    4ms
    Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (clinicaltrials.gov)
    P1, N=66, Suspended, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Sep 2028 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Sep 2028
    Trial completion date • Trial suspension • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ZEN-3694 • ABP 206 (nivolumab biosimilar)
    5ms
    Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, National Cancer Institute (NCI) | Phase classification: P1 --> P1/2
    Phase classification
    |
    BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    cisplatin • carboplatin • paclitaxel • etoposide IV • ZEN-3694
    6ms
    Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=49, Recruiting, National Cancer Institute (NCI) | N=30 --> 49
    Enrollment change
    |
    Jingzhuda (entinostat) • ZEN-3694
    6ms
    Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (clinicaltrials.gov)
    P1, N=36, Recruiting, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1 | N=55 --> 36
    Phase classification • Enrollment change
    |
    BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    cisplatin • carboplatin • paclitaxel • etoposide IV • ZEN-3694